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ABSTRACT
Healthy vascular function is primarily regulated by several factors including EDRF (endothelium-
dependent relaxing factor), EDCF (endothelium-dependent contracting factor) and EDHF
(endothelium-dependent hyperpolarizing factor). Vascular dysfunction or injury induced by aging,
smoking, inﬂammation, trauma, hyperlipidaemia and hyperglycaemia are among a myriad of risk
factors that may contribute to the pathogenesis of many cardiovascular diseases, such as hyper-
tension, diabetes and atherosclerosis. However, the exact mechanisms underlying the impaired
vascular activity remain unresolved and there is no current scientiﬁc consensus. Accumulating
evidence suggests that the inﬂammatory cytokine TNF (tumour necrosis factor)-α plays a pivotal
role in the disruption of macrovascular and microvascular circulation both in vivo and in vitro.
AGEs (advanced glycation end-products)/RAGE (receptor for AGEs), LOX-1 [lectin-like oxidized
low-density lipoprotein receptor-1) and NF-κB (nuclear factor κB) signalling play key roles in
TNF-α expression through an increase in circulating and/or local vascular TNF-α production. The
increaseinTNF-α expressioninducestheproductionofROS(reactiveoxygenspecies),resultingin
endothelial dysfunction in many pathophysiological conditions. Lipid metabolism, dietary supple-
mentsandphysicalactivityaffectTNF-α expression.TheinteractionbetweenTNF-α andstemcells
is also important in terms of vascular repair or regeneration. Careful scrutiny of these factors may
help elucidate the mechanisms that induce vascular dysfunction. The focus of the present review is
to summarize recent evidence showing the role of TNF-α in vascular dysfunction in cardiovascular
disease. We believe these ﬁndings may prompt new directions for targeting inﬂammation in future
therapies.
Key words: inﬂammation, macrovascular circulation, microvascular circulation, nitric oxide, reactive oxygen species (ROS), tumour
necrosis factor-α (TNF-α).
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IκB kinase; NOS, NO synthase; cNOS, constitutive NOS; eNOS, endothelial NOS; iNOS, inducible NOS; nNOS, neuronal NOS;
O2
−, superoxide radical; ONOO−, peroxynitrite; PGI2, prostacyclin; RA, rheumatoid arthritis; RAGE, receptor for AGEs; ROS,
reactive oxygen species; SCF, stem cell factor; SK1, sphingosine kinase 1; Sph1P, sphingosine-1-phosphate; TNF, tumour necrosis
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Figure 1 Pivotal role of TNF-α in vascular dysfunction
Even though numerous risk factors, such as physical inactivity, smoking and over-nutrition, appear to contribute to the development of vascular dysfunction, normal
aging is also an independent factor in the aetiology of cardiovascular diseases. There is evidence, however, that those seemingly diverse processes converge on
modulating TNF-α signalling to lead to the generation of dysfunctional endothelium and the onset of vascular diseases. TNF-α induces the gene expression of various
inﬂammatory cytokines and chemokines, either dependently or independently of the activation of transcriptional factors, such as NF-κB and AP-1 (activator protein 1).
This TNF-α-mediated signalling initiates and accelerates atherogenesis, thrombosis, vascular remodelling, vascular inﬂammation, endothelium apoptosis, vascular oxidative
stress and impaired NO bioavailability, which contribute to the blunted vascular function. Dietary supplements and exercise favourably reduce the risk of vascular
dysfunction by inhibiting TNF-α production and (or) TNF-α-mediated signalling. Risk factors in orange demonstrate those factors that converge on TNF-α to induce
vascular dysfunction. Factors in green denote those that protect against vascular damage mediated by TNF-α expression and signalling. TNF-α-induced pathophysiological
conditions related to vascular function are shown in blue. Both vascular risk factors and protective factors affect the regulation of vascular functions by modulating
TNF-α production and downstream signalling. MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; TF, tissue factor.
INTRODUCTION
IHD (ischaemic heart disease) accounts for over 500000
deaths annually in the United States. AMI (acute
myocardial infarction), also known as a heart attack [1],
is a common complication of IHD. AMI usually results
from plaque rupture with thrombus formation in a
coronary vessel, resulting in an acute reduction in blood
supply to the downstream myocardium. Paradoxically,
re-establishment of the blood supply can exacerbate
vascular injury. Treatment of AMI, such as thrombolysis
and other means of revascularization, often induce
further vascular injury, which contributes to morbidity
and mortality before normal cardiac function restores.
The endothelium is a functional barrier between the
blood vessel and the blood stream, and was once con-
sidered to be relatively inert [2]. However, various func-
tionsofECs(endothelialcells)havebeenelucidated,such
as the control of ﬁbrinolysis, coagulation, vascular tone,
growth and immune response. The endothelium modu-
lates vascular tone through several factors, including
NO, PGI2 (prostacyclin) and EDHF (endothelium-
dependent hyperpolarizing factor). A hallmark of IHD is
the development of coronary vascular lesions, which are
linked to well-known risk factors, such as diabetes and
obesity conditions associated with increased levels of
inﬂammatory markers (Figure 1). IHD accelerates the
atherosclerotic process, the earliest event of which is
endothelial dysfunction.
ROLE OF TNF-α (TUMOUR NECROSIS
FACTOR-α) IN ENDOTHELIAL DYSFUNCTION
NO is a free radical generated by NOS (NO synthase) in
a two-step ﬁve-electron oxidation of the terminal guan-
idinonitrogenofl-arginine.ThreeisoformsofNOShave
been characterized: eNOS (endothelial NOS), nNOS
(neuronal NOS) and iNOS (inducible NOS). eNOS and
nNOS are also called cNOS (constitutive NOS) [3].
TNF-α regulates NOS expression and/or activity, which
exerts direct effects on NO production; for example,
human aortic ECs treated with TNF-α for 8 h had
induced iNOS mRNA expression, but down-regulated
eNOS expression [4]. Other studies have also shown that
TNF-α signiﬁcantly decreased eNOS expression in ECs
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[5–8]. Unlike eNOS, iNOS is transcriptionally regulated
and not normally produced in most cells. iNOS-derived
RNS (reactive nitrogen species) initiate an ONOO−
(peroxynitrite)-mediated mechanism and therefore con-
tribute to nitrative stress and impair endothelial function.
Several mechanisms have been suggested for the
induction/activationofNOSbyTNF-α.Yoshizumietal.
[9] demonstrated that TNF-α markedly reduced mRNA
levels of cNOS in HUVECs (human umbilical vein ECs)
in a dose- and time-dependent manner without changing
the rate of cNOS gene transcription. TNF-α appears to
decrease cNOS mRNA levels by increasing the rate of
mRNA degradation Another study, however, suggested
that TNF-α increases eNOS activity in HUVECs [10].
ActivationofeNOSbyTNF-α requiresactivationofAkt
(protein kinase B), a known eNOS activator, via Sph1P
(sphingosine-1-phosphate)receptoractivation.Sph1Pre-
ceptor is activated by Sph1P, a sphingolipid involved in
proliferation, survival, migration and differentiation of
these cells, generated through N-SMase2 (neutral sphin-
gomyelinase 2) and SK1 (sphingosine kinase 1) activation
[10]. TNF-α-mediated activation of eNOS is accompan-
ied by increased NO generation, which exerts protective
effects on DC (dendritic cell) adhesion to endothelium
induced by TNF-α itself. It has also been suggested
that TNF-α may increase iNOS expression by activating
NF-κB (nuclear factor κB) [11]. TNF-α-induced iNOS
mRNA expression in microvascular ECs could be de-
creased by rooperol (a dicatechol from the South African
plant Hypoxis rooperi) administration, which is an anti-
inﬂammatoryagentinthetreatmentofseveralinﬂammat-
ory disorders [12]. In HUVECs, the effect of TNF-α on
iNOS expression was not affected by statin treatment,
whereas reduced eNOS expression was reversed by
rosuvastatin and ceruvastatin by inhibiting HMG-
CoA (3-hydroxy-3-methylglutaryl-CoA) reductase and
subsequent blocking of isoprenoid synthesis [13].
Evidence suggests that TNF-α impairs endothelium-
dependent and NO-mediated vasodilation in various
vascular beds, e.g. mouse coronary arterioles [14], rat
coronary arterioles [15], cat carotid arteries [16] and
bovine small coronary arteries [17]. Picchi et al. [15]
demonstrated that endothelial dysfunction in pre-
diabetic metabolic syndrome is a result of the effects of
TNF-α and the subsequent production of O2
− (super-
oxide radical). We have assessed the role of TNF-α in
I/R (ischaemia/reperfusion) injury in TNF 1.6 mice,
which overexpress TNF-α in cardiac tissue. Myocardial
I/R initiated the increase in the expression of TNF-α,
which induced activation of XO (xanthine oxidase) and
the production of O2
−, leading to coronary endothelial
dysfunction [18]. Gao et al. [14] showed that AGE
(advanced glycation end-product)/RAGE (receptor
for AGEs) and NF-κB signalling play a pivotal role
in elevating circulating and/or local vascular TNF-α
production.TheincreasedTNF-α expressioninducesthe
production of ROS (reactive oxygen species), leading to
endothelial dysfunction in Type 2 diabetes. Endothelial
dysfunction associated with TNF-α in pathophysiolo-
gical conditions is linked to excess production of ROS
and a decrease in NO bioavailability.
TNF-α appears to decrease the bioavailability of NO
by (i) diminishing the production of NO [6,15,17,19],
and (ii) enhancing the removal of NO [14]. Picchi et al.
[15] reported that the real-time production of NO in
isolated coronary arteries from ZOF rats (Zucker Obese
Fatty rats; a model of pre-diabetic metabolic syndrome)
and ACh (acetylcholine)-induced NO production were
signiﬁcantly lower in ZOF rats compared with the lean
control rats. This result suggested that higher concen-
trations of circulating and protein expression of TNF-α
diminished NO bioavailability in ZOF rat coronary
arteries via the decreased expression of eNOS (Figure 2).
ManystudieshaveshownthatthedirecteffectsofTNF-α
on eNOS are via down-regulating eNOS expression
and diminishing NO production in diverse vasculatures
[6,10,14,15]. In addition to eNOS, other factors are also
involved in regulating NO production, and one of those
factors is a functional citrulline/NO cycle [20–23]. The
citrulline/NO cycle is regulated by ASS (argininosuccin-
ate synthase). NO is synthesized from the conversion
of l-arginine into l-citrulline mediated by eNOS, and
ASS catalyses the rate-limiting step in the arginine
regenerationthroughthecitrulline/NOcycleandappears
to be co-ordinately regulated with eNOS activity [24]
(Figure 2). Goodwin et al. [6] have shown that TNF-α
diminished the protein and mRNA expression of ASS in
aortic ECs and directly resulted in the reduced produc-
tion of NO. Gao and co-workers [14,15] reported that
TNF-α impaired NO-mediated vasodilation in Type 2
diabetic coronary arterioles. A neutralizing antibody to
TNF-α decreasedtheformationofROS(O2
−,ONOO−
and H2O2) and improved NO-mediated vasodilation.
TNF-α stimulates the endothelial generation of ROS by
activation of NADPH oxidase, perhaps via the subunits
gp91phox,N O X - 1 ,p 4 7 phox and p22phox (Figure 2).
NO has been implicated as the major mediator of
endothelium-dependentrelaxation,butEDHFalsoplays
an important role in regulating vascular tone and vaso-
reactivity, particularly in resistance blood vessels, where
a small change in membrane potential causes a signiﬁcant
change in diameter [25]. A number of different factors
have been considered as candidates for EDHFs, such as
K+ ions, EET (epoxyeicosatrienoic acid) and H2O2 [26].
CurrentevidencesuggeststhatEDHF-inducedresponses
may be mediated by one or a combination of several
factors in different vasculatures [25]. Type 2 diabetes
impairs EDHF-mediated vasodilation [27]; however,
the mechanisms have not been clearly elucidated. For
example, the role of TNF-α in EDHF-mediated vascular
dysfunction is controversial. Wimalasundera et al. [28]
reported that TNF-α did not inhibit EDHF-dependent
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Figure 2 Role of TNF-α in endothelial dysfunction
TNF-α reduces the production of NO through the inhibition of the enzyme activities of ASS and eNOS, and enhances the removal of NO through the increase in
NADPH-dependent O2
− production to react with NO to form ONOO−. As a consequence, TNF-α decreases the bioavailability of NO to induce relaxation of smooth
muscle in the vasculature. TNF-α also diminishes EETs, one of the candidate EDHFs, via the inhibition of cytochrome P450 (CYP 450) enzyme activity. AA, arachidonic
acid.
vasodilation, whereas Gillham et al. [29] measured a
direct effect of TNF-α on EDHF-mediated vasodilation
by incubation of 1 nmol/l TNF-α for 1 or 2 h with blood
vessels from human omental arteries and showed that
TNF-α impaired EDHF-mediated dilation. In addition,
Kessler et al. [30] found that TNF-α reduced EDHF
synthesis with direct measurement of hyperpolarization
from porcine coronary arteries, and Park et al. [30a]
have shown that EDHF-mediated dilation in coronary
arterioles from Type 2 diabetic mice null for TNF-α
(dbTNF−/dbTNF−) was enhanced compared with Type 2
diabetic (db/db) mice. The possible mechanism of
impaired EDHF-mediated vasodilation by TNF-α
may be via EETs, one of the candidates for EDHF.
EETs are synthesized in the ECs from AA (arachidonic
acid) through cytochrome P450 oxygenase. TNF-α
down-regulated the protein expression of cytochrome
P450 2C, which is the major family of cytochrome P450
mono-oxygenases in porcine aortic ECs [30] (Figure 2).
EFFECT OF TNF-α ON ROS PRODUCTION
The production of ROS can stimulate a cytokine cascade
through NF-κB-induced transcriptional events, which
then induce the expression of TNF-α [31,32]. TNF-α
stimulates O2
− production in neutrophils and ECs, re-
portedly via CAPK (ceramide-activated protein kinase),
NADPH oxidase [33], XO [34], NOS [35,36] etc. Many
experimental studies suggest that increased O2
− pro-
duction accounts for a signiﬁcant proportion of the NO
deﬁcit in diabetic vessels. Potential sources of vascular
O2
− production include NADPH-dependent oxidases
[37,38], XO [39], lipoxygenase, mitochondrial oxi-
dase and uncoupled NOS [40]. NADPH oxidase appears
to be the principal source of O2
− production in several
animalmodelsofvasculardisease,includingdiabetes[41].
Furthermore, NADPH oxidase proteins and activity are
present in human blood vessels, including atherosclerotic
coronary arteries [42], and in saphenous veins and mam-
mary arteries from patients with coronary artery disease
[43], which suggests that this oxidase system plays an
importantroleincardiovasculardiseases[44].Guziketal.
[45] have described the mechanisms of increased O2
−
production in human diabetes mellitus. They found that
basal O2
− release was signiﬁcantly elevated in vessels
from patients with diabetes. Western immunoblot ana-
lysis showed increased levels of the p22phox membrane-
bound subunit and the p67phox and p47phox cytosolic
subunits in both veins and arteries from patients with
diabetes. Moreover, engagement of RAGE triggers
signalling cascades in which activation of NADPH
oxidase recruits multiple downstream pathways, includ-
ing p21ras, the MAPKs (mitogen-activated protein
kinases), the JAK (Janus kinase)/STAT (signal trans-
ducer and activator of transcription) pathway, PI3K
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(phosphoinositide 3-kinase), cdc42/rac and nuclear
translocation of NF-κB [46]. As mentioned previously,
NF-κB can be considered as a link between TNF-α
and AGE/RAGE signalling because TNF-α enhanced
RAGE expression by NF-κB activation [32,47–50].
TNF-α activates the transcription of NF-κB, which
regulates the expression of genes involved in inﬂamma-
tion,oxidativestressandendothelialdysfunction[51–53].
TNF-α initiates the signalling cascades via the IKK [IκB
(inhibitor of NF-κB) kinase] complex, which contains
IKKα and IKKβ.T N F - α predominantly initiates
signalling cascades acting through IKKβ [54,55]. The
inhibitoryproteinIκBα isphosphorylated,ubiquitinated
and degraded by the proteasome, releasing NF-κBt o
translocate into the nucleus. Under normal physiological
conditions, the inﬂammatory response is terminated
by binding NF-κB with the inhibitory protein IκB
[56,57].InECs,NF-κBregulatestheinducibleexpression
of genes encoding TNF-α, IL (interleukin)-6, MCP-1
(monocyte chemoattractant protein-1) and adhesion
molecules in diabetic mice [58]. Shoelson et al. [59]
have detailed the role of IKKβ in inﬂammation-induced
insulin resistance in obesity and Type 2 diabetes, with
the genetic disruption of the IKKβ signalling pathways
shown to improve insulin resistance. We have shown that
blockade of IKKβ activity by sodium salicylate not only
prevented insulin resistance, but also preserved coronary
arteriolar vasodilation in Type 2 diabetic mice (J. Yang,
Y. Park, H. Zhang, X. Xu, G.A. Laine, K.C. Dellsperger
and C. Zhang, unpublished work). Furthermore, obese
insulin-resistant subjects have endothelial dysfunction
and resistance to endothelium-dependent insulin-
mediated vasodilation [60,61]. Augmentation of insulin
signalling may contribute to endothelium-dependent
NO-mediated vasodilation in diabetic mice treated with
sodium salicylate (J. Yang, Y. Park, H. Zhang, X. Xu,
G.A. Laine, K.C. Dellsperger and C. Zhang, unpublished
work). NF-κB induces TNF-α signalling to accentuate
oxidative stress and endothelial dysfunction induced via
an IKKβ-dependent mechanism, which may be associ-
ated with inﬂammatory and insulin signalling pathways
seen in Type 2 diabetes. AGE/RAGE signalling, as noted
above, stimulates the production of O2
−, which could
exacerbate both oxidative stress and impaired bioavailab-
ility of NO. Thus it appears that impaired NO function
maybethedirectresultoftheoverproductionofO2
− in-
duced by TNF-α and AGE/RAGE. O2
− is the chemical
p r e c u r s o rt om a n yR O S ,s u c ha sH 2O2 and ONOO−.
ROLE OF TNF-α IN LIPID METABOLISM
Both clinical observations and basic research have
indicated a potential link between inﬂammation and
lipid metabolism. TNF-α acts as a key cytokine that
affectsandmediatesintermediarymetabolism,andaclose
relationship between TNF-α and lipid metabolism is
supported by several studies. In patients with hyper-
lipidaemia, TNF-α levels correlated signiﬁcantly with
the concentrations of VLDL (very-low-density lipo-
protein) -triacylglycerol (triglyceride) and -cholesterol,
and negatively with HDL (high-density lipoprotein)-
cholesterol [62]. Simvastatin and atorvastatin decrease
TNF-α levels in subjects with hyperlipidaemia and
hypercholesterolaemia [63–65]. Furthermore, patients
with type IIa and IIb dyslipidaemia have an abnormal
pattern of TNF-α. HMG-CoA reductase inhibitors
(statins) and PPAR-α (peroxisome-proliferator-activated
receptor-α) activators (ﬁbrates) normalize TNF-α levels
[66]. A high-cholesterol diet induces high levels of serum
TNF-α concentration, whereas the mRNA expression
of TNF-α is signiﬁcantly reduced by atorvastatin
treatment in hypercholesterolaemic rabbits [67]. TNF-α
blockade could signiﬁcantly affect lipid metabolism.
Short-term administration of adaluminab, a fully human
anti-TNF-α monoclonalantibody,topatientswithactive
RA (rheumatoid arthritis), signiﬁcantly increased HDL-
cholesterol concentrations; in addition, the atherogenic
index decreased [68]. Inﬂiximab, a chimaeric anti-TNF-α
monoclonal antibody, had similar results [69–71].
Administration of TNF-α has been demonstrated to
directlyinterferewiththeplasmalipidlevelandmetabolic
pathways. In mice, administration of TNF-α results in
an acute increase in plasma triacylgycerol concentrations
of 85%, and inhibition of TNF-α activity blocked the
increaseinserumtriacylglycerolsthatischaracteristically
observed after LPS (lipopolysaccharide) treatment
[72,73]. The effect of TNF-α on lipid metabolism is
complicated, and the mechanisms are complex and take
place at different levels and through different steps, from
affectingproteinexpressiontoinhibitingenzymeactivity.
Collectively, these studies prompt the question: why
does TNF-α produce different responses in different
situations? With this controversial background and
in conjunction with previous studies, there is ample
rationale to study the role of TNF-α in lipid metabolism.
AGING AND TNF-α
Epidemiological studies have shown that even normal
aging is an independent risk factor for cardiovascular
diseases [74]. An aging-induced pro-inﬂammatory
shift plays an important role in vascular regulatory
mechanisms. Previous studies have suggested that
circulatinglevelsofTNF-αareelevatedintheelderly[75].
Increased TNF-α production has been demonstrated in
carotidarteries,aorticwall[76]andcoronaryarteries[77]
of aged rodents. Age-related up-regulation of TNF-α in
rat coronary arteries induced endothelial apoptotic cell
death, which may lead to impaired endothelial function
in the elderly [77]. At the cellular level, TNF-α reduced
t h eg r o w t hr a t ea n din vitro life span of ECs in both
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dose- and treatment-length-dependent manners, sugges-
tingthattheagingofECsismodiﬁedbyTNF-α exposure
[78]. In contrast, inhibition of TNF-α exerts beneﬁcial
effects in aging-related pathophysiological changes.
In vivo, chronic TNF-α inhibition by etanercept
improves ﬂow-mediated arterial dilation in resistance
arteriesofagedfemalerats[79],aswellasdown-regulates
theexpressionofinﬂammatorymarkers,includingiNOS
and ICAM-1 (intercellular adhesion molecule-1), which
are abundantly expressed in aged vessels. In carotid
arteries of young animals, recombinant TNF-α induced
endothelial dysfunction, oxidative stress and increased
apoptosis and pro-inﬂammatory gene expression,
mimicking many of the symptoms of vascular aging [74].
Thus dysregulation of TNF-α expression is associated
with vascular aging, and anti-TNF-α treatment exerts
anti-aging vasculoprotective effects.
To sum up, aging is an independent factor in vascular
dysfunction. In the presence of other risk factors, such
as smoking and over-nutrition, the development of
endothelial dysfunction might be accelerated. Those risk
factors converge on TNF-α to cause vascular oxidative
stress, vascular remodelling, thrombosis, cell inﬁltration,
apoptosis, vascular inﬂammation etc., and therefore lead
to vascular damage (Figure 1).
TNF-α AND HIGH-FAT AND
HIGH-CARBOHYDRATE DIETS
The effects of over-nutrition on endothelial dysfunction
in healthy subjects and subjects with dyslipidaemia, the
metabolic syndrome and diabetes have been examined
in many studies. Endothelial function was markedly
impaired by a high-fat meal that caused an acute
hypertriacylglycerolaemia. This impairment was evident
inpatientswithdyslipidaemiawithbaselinehypertriacyl-
glycerolaemia, but not in controls with normotriacylgly-
cerolaemia [80]. Compared with the control group, sub-
jects with metabolic syndrome had reduced endothelial
function, as assessed using the l-arginine test, and higher
circulating levels of TNF-α. Following the high-fat meal,
both triacylglycerol and TNF-α levels increased more
in subjects with the metabolic syndrome than in normal
subjects, whereas endothelial function decreased more in
subjects with the metabolic syndrome [81]. Moreover,
in healthy subjects, the high-fat meal increased plasma
levels of TNF-α, IL-6, ICAM-1 and VCAM-1 (vascular
cell adhesion molecule-1), while the high-carbohydrate
meal had no effects in these subjects. In patients with
diabetes, both meals signiﬁcantly increased cytokine and
adhesion molecule levels, but the increase lasted longer
following the high-fat meal [82]. On the basis of the sig-
niﬁcant relationship between increases in TNF-α levels
and decreases in endothelial function in subjects with the
metabolicsyndromeanddiabetes[81],themechanismsof
TNF-α-induced endothelial dysfunction following high-
energydietshasbeenextensivelystudiedatthemolecular
and cellular levels. Intraluminal butter administration
signiﬁcantly increased TNF-α expression in lamina
proprial macrophage and lymphocyte adherence to
intestinal microvessels, accompanied by increases in the
expression levels of ICAM-1, MAdCAM-1 (mucosal
adhesion cell adhesion molecule-1) and VCAM-1.
Furthermore, anti-TNF-α treatment attenuated the
enhanced expression of adhesion molecules induced
by butter administration [83]. Therefore high-energy
diets may cause endothelial dysfunction, as well as
potentiate TNF-α-mediated EC injury [84]. Reducing
saturated fat and dietary cholesterol intake and avoiding
excess calories remains the cornerstone of the dietary
approaches to decrease the risk of vascular diseases.
ROLE OF EXERCISE IN CARDIOVASCULAR
DISEASE
Pro-inﬂammationevents,suchastheincreasesinTNF-α,
CRP (C-reactive protein), IL-6 and resistin, appear
to produce their harmful effects, at least in part, by
inducing endothelial dysfunction and also by decreasing
endothelial NO generation. NO inhibits platelet
adherence and aggregation, suppresses vasoconstriction,
reduces the adherence of leucocytes to the endothelium
and suppresses the proliferation of VSMCs (vascular
smooth muscle cells) [85]. Of these pro-inﬂammatory
cytokines, TNF-α is a key player in systemic low-
level inﬂammation through stimulating the expression
of adhesion molecules on ECs and thereby inducing
endothelial dysfunction [85,86]. TNF-α is a strong
biological driver of the metabolic syndrome, which
is characterized by abdominal obesity, hypertension, a
reducedlevelofHDL,elevatedtriacylglycerolsandhigh-
fasting glucose, and constitutes an important risk factor
in atherosclerosis and Type 2 diabetes [86]. Keller et al.
[87] have reported that TNF-α overexpression returned
to normal levels after 1 h of acute swimming exercise
in TNFR (TNF receptor)-knockout mice. In addition,
chronic exercise appears to suppress pro-inﬂammatory
factors, such as TNF-α, CRP and IL-6, and augment
anti-inﬂammatoryfactors,including IL-4,IL-10,TGF-β
(transforming growth factor-β) and adiponectin, even
though these results showed discrepancies according to
themodes,intensityandtimedurationofexercise[86,88–
90]. Therefore the anti-inﬂammatory effects of exercise
may offer protection against TNF-α-induced insulin res-
istance and the secondary development of cardiovascular
dysfunction. In summary, regular exercise contributes
to the prevention of cardiovascular dysfunction by con-
trolling traditional cardiovascular risk factors, including
HDL- and LDL (low-density lipoprotein)-cholesterol,
improving antioxidant factors, such as SOD (superoxide
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dismutase)andglutathioneperoxidase,elevatingtheanti-
inﬂammatoryeffectandsuppressingTNF-α,whichisthe
main pro-inﬂammatory cytokine (Figure 1).
TNF-α AND STEM CELLS/PROGENITOR
CELLS
Stem and progenitor cells possess the ability to self-
regenerate and differentiate into many cell types,
including cardiovascular-speciﬁc forms. The role of stem
cells and progenitor cells in cardiovascular diseases has
been widely investigated. As inﬂammation is involved
in most cardiovascular diseases, understanding the
communication and interaction between TNF-α and
stem cells is important. Clinical evidence has shown that
the serum TNF-α level was negatively correlated with
peripheral blood CD34+ stem cells and circulating EPCs
(endothelial progenitor cells) in the early and late stages
of congestive heart failure, which might be related to the
myelosuppressive effect of TNF-α [91]. A similar ob-
servation was also reported in a mouse model of conges-
tive heart failure, with increased serum TNF-α levels and
decreasedbonemarrowprogenitorcells[92].Invitrostu-
dies have indicated a causal relationship between TNF-α
and suppression of haemopoietic stem cell growth.
Rusten et al. [93] reported that TNF-α directly inhibited
SCF (stemcell factor)-stimulatedproliferationof CD34+
haemopoietic progenitor cells. Similar results were also
demonstrated in human CD34+ myeloid leukaemia
cells and primitive human bone marrow progenitor cells
(CD34+CD38−) [94,95]. Interestingly, the inhibitory
effects of TNF-α in these studies were consistently
mediatedbyTNFR-I,butnotTNFR-II.Onthecontrary,
the TNFR-II signalling pathway has a protective proﬁle
on stem cell function. Chen et al. [96] have demonstrated
that TNF-α-overexpressing cardiomyocytes attracted
increased numbers of embryonic stem cells, mediated
by TNFR-II in the embryonic stem cells. Treatment
with TNFR-II-overexpressing mesenchymal stem
cells attenuated cardiac dysfunction after myocardial
infarction [97]. The expression of TNFR-II on bone-
marrow-derived progenitor cells was required for
ischaemia-induced neovascularization [98]. Thus distinct
effects of TNF-α are mediated by different subtypes of
TNFRs in stem cells, whereas the overall effect might be
dependent on the expression level and ratio of these two
receptors.
Apart from the direct effects, TNF-α is able to indir-
ectly inﬂuence the fate of stem cells. TNF-α markedly
stimulates production of GM-CSF (granulocyte/macro-
phage colony-stimulating factor), a strong mobilizer of
stem cells from bone marrow [99]. Activation of the
TNF-α/Faspathwayinlymphocytesinthebonemarrow
may play a pathogenic role in suppressing haemopoiesis
[92]. In the peripheral circulation, EPC adhesion to
HUVECs was signiﬁcantly increased by TNF-α pre-
treatment with HUVECs; the adhesion was mediated by
the up-regulation of E-selectin on the cells. Interestingly,
when EPCs rather than HUVECs were stimulated with
TNF-α, EPC adhesion to HUVECs was not induced
[100]. TNF-α also has effects on stem cell differentiation:
administration of TNF-α switched the differentiation of
thesecellsfromgranulocytestoalmostcompleteproduc-
tionofmacrophageswhenmouseLin−Sac+ haemopoietic
progenitor cells were cultured with SCF and IL-7
[101].
In summary, TNF-α plays an important role in regu-
latingstem-cell-mediatedvascularreparationandremod-
elling; however, the overall effect of TNF-α on stem cell
mobilization, proliferation and function is complicated,
depending on the TNFR subtypes and the presence of
other cytokines as well as other cells (Figure 1).
ANTI-TNF-α TREATMENT IN CLINICAL
STUDIES
As a potent pro-inﬂammatory trigger, the central role of
TNF-α in vascular dysfunction has been demonstrated
by the ability of agents that block the action of TNF-α
to treat a range of cardiovascular disorders and
inﬂammatory conditions, including AMI, heart failure,
RA, diabetes, hyperlipidaemia and COPD (chronic
obstructive pulmonary disease).
Intra-arterial TNF-α infusion in healthy volunteers
and patients provides direct evidence about TNF-α-
stimulated vascular dysfunction. In healthy volunteers,
intra-arterial TNF-α at a dose of 80 or 240 ng/min for
30 min resulted in an acute local vascular inﬂammation
that was associated with impaired endothelium-de-
pendentvasomotion,aswellasasustainedandsubstantial
increase in endothelial t-PA (tissue plasminogen
activator) release [102]. A dose of 17 ng/min for 60 min
increased the basal bioavailability of the vasoconstrictor
prostaglandin and reduced the basal bioavailability
of NO, although it had no effects on endothelium-
dependent vasomotion in healthy subjects [103]. In
patients with coronary heart disease, intra-arterial
TNF-α at a dose of 80 ng/min for 60 min caused an
increase in t-PA concentrations without affecting blood
ﬂow [104]. In patients with Type 2 diabetes, intra-arterial
infusion with TNF-α (10 ng·100 ml−1 of forearm
volume·min−1 for 2 h) induced the impairment of
endothelial function in resistance vessels [105].
On the basis of the important role of TNF-α in
inducing endothelial dysfunction, clinical trials are under
way to investigate the use of the three currently available
TNF-α inhibitors (inﬂiximab, etanercept or adalimu-
mab),aswellasothers,invasculardisordersaccompanied
byseveraldiseases.Chronicanti-inﬂammatorytreatment
with the anti-TNF-α antibody inﬂiximab improved
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endothelial function of the brachial artery in patients
with RA [106,107], systemic vasculitis [108] and Crohn’s
disease [109]. Anti-TNF-α therapy with etanercept,
a recombinant TNFR that binds to and functionally
inactivates TNF-α, and adalimumab, a fully human
monoclonal antibody directed against TNF-α, were also
able to improve endothelial function in patients with RA
[110,111]. In patients with advanced heart failure, etaner-
cept improves systemic endothelial vasodilator capacity
[112], although studies using anti-TNF-α antibodies in
chronic heart failure have been terminated prematurely
owing to a lack of beneﬁt on the rate of death or hospital-
ization [113]. However, although short-term etanercept
treatment had a signiﬁcant beneﬁcial effect on systemic
inﬂammatory markers, no improvement in vascular or
metabolic insulin sensitivity was observed in obese
patientswithType2diabetes[114].InadditiontoTNF-α
inhibitors, various statins, such as atorvastatin and sim-
vastatin, and the ACEI (angiotensin-converting enzyme
inhibitor) quinapril were reported to decrease circulating
TNF-α levels, as well as improve endothelial function in
patientswithType2diabetes,congestiveheartfailure,RA
orhyperlipidaemia[65,115–121].Therefore,althoughthe
efﬁcacy and safety of anti-TNF-α biologicals have been
extensively studied in treating vascular complications
of inﬂammatory diseases, such as RA and Crohn’s
disease, the use of TNF-α inhibitors and antibodies in
cardiovasculardiseaseandType2diabetesmayneedtobe
evaluated further by randomized controlled clinical trials
or long-term observational studies. Furthermore, direct
evidencemaybeneededtoaddressthecausalrelationship
between the effects of statins and ACEIs in attenu-
ating TNF-α production and improving endothelial
function.
To sum up, the evidence above suggests an important
role of TNF-α in vascular dysfunction. These studies
may support the long-term use of drugs that block
TNF-α function to reduce the high incidence of cardi-
ovasculardisordersandvascularcomplicationsinvarious
diseases.
CONCLUDING REMARKS
Recent research in animal models and humans provides
compelling evidence identifying TNF-α as one of several
regulators of vascular homoeostasis. Major progress has
been made in unveiling the molecular mechanisms that
underlie the multiple vasculoprotective actions of anti-
TNF-α. However, many of the mechanisms proposed
in the present review are based on in vitro studies and,
thus,thephysiologicalrelevanceoftheseﬁndingsremains
to be conﬁrmed in vivo. Our understanding of TNF-α
and TNFR, especially with respect to structure–function
relationshipsandtheirpathophysiologicalroleinvascular
dysfunction, is still in its infancy. There have been trials
using TNF-α antagonists in heart failure, but there are
very few trials using TNF-α antagonists (soluble recep-
tors) in vascular disease. Although TNF-α antagonists
(soluble receptors) have been shown to lack beneﬁts on
therateofdeathorhospitalizationinchronicheartfailure,
therehavebeentrialsusingTNF-αantagonistsinvascular
complications of inﬂammatory diseases, such as RA
and Crohn’s diseases. These studies suggested beneﬁcial
effects of anti-TNF-α treatment in improving vascular
function;however,thereareveryfewtrialsapplyinganti-
TNF-α treatment in vascular diseases and cardiovascular
disorders related to Type 2 diabetes and the metabolic
syndrome. Is it time to revisit antagonism of TNF-α in
cardiovasculardiseases?Webelievethatfurtherinvestiga-
tionsinthisexcitingﬁeldcouldfacilitatethedevelopment
ofselectiveTNF-α antagonistswiththerapeuticpotential
in the management of diabetes and other vascular
diseases.
FUNDING
This study was supported by a Pﬁzer Atorvastatin
Research Award [grant number 2004-37)]; an American
Heart Association Scientist Development Grant [grant
number 110350047A]; and the National Institutes of
Health [grant number RO1-HL077566] (to C.Z.).
REFERENCES
1 Guyton, A. C. and Hall, J. E. (1997) Human Physiology
and Mechanism of Disease, 6th edn, Saunders,
Philadelphia
2 Stenvinkel, P. (2001) Endothelial dysfunction and
inﬂammation: is there a link? Nephrol. Dial. Transplant.
16, 1968–1971
3 Moncada, S., Palmer, R. M. and Higgs, E. A. (1991) Nitric
oxide: physiology, pathophysiology, and pharmacology.
Pharmacol. Rev. 43, 109–142
4 MacNaul, K. L. and Hutchinson, N. I. (1993) Differential
expression of iNOS and cNOS mRNA in human vascular
smooth muscle cells and endothelial cells under normal
and inﬂammatory conditions. Biochem. Biophys.
Res. Commun. 196, 1330–1334
5 Zhang, J., Patel, J. M., Li, Y. D. and Block, E. R. (1997)
Proinﬂammatory cytokines downregulate gene
expression and activity of constitutive nitric oxide
synthase in porcine pulmonary artery endothelial cells.
Res. Commun. Mol. Pathol. Pharmacol. 96, 71–87
6 Goodwin, B. L., Pendleton, L. C., Levy, M. M.,
Solomonson, L. P. and Eichler, D. C. (2007) Tumor
necrosis factor-α reduces argininosuccinate synthase
expression and nitric oxide production in aortic
endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 293,
H1115–H1121
7 Xia, Z., Liu, M., Wu, Y. et al. (2006) N-acetylcysteine
attenuates TNF-α-induced human vascular endothelial
cell apoptosis and restores eNOS expression.
Eur. J. Pharmacol. 550, 134–142
8 Seidel, M., Billert, H. and Kurpisz, M. (2006) Regulation
of eNOS expression in HCAEC cell line treated with
opioids and proinﬂammatory cytokines. Kardiol. Pol. 64,
153–158
9 Yoshizumi, M., Perrella, M. A., Burnett, Jr, J. C. and Lee,
M. E. (1993) Tumor necrosis factor downregulates an
endothelial nitric oxide synthase mRNA by shortening its
half-life. Circ. Res. 73, 205–209
C   The Authors Journal compilation C   2009 Biochemical Society
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.Role of TNF-α in vascular dysfunction 227
10 De Palma, C., Meacci, E., Perrotta, C., Bruni, P. and
Clementi, E. (2006) Endothelial nitric oxide synthase
activation by tumor necrosis factor α through
neutral sphingomyelinase 2, sphingosine kinase 1, and
sphingosine 1 phosphate receptors: a novel pathway
relevant to the pathophysiology of endothelium.
Arterioscler. Thromb. Vasc. Biol. 26, 99–105
11 Zhong, L., You, J. and Sun, Q. (1999) The role of NF-κB
in the TNF-α-induced endothelial cell apoptosis.
Zhonghua Yixue Zazhi 79, 863–866
12 Bereta, J., Bereta, M., Allison, A. C., Kruger, P. B. and
Koj, A. (1997) Inhibitory effect of di-catechol rooperol on
VCAM-1 and iNOS expression in cytokine-stimulated
endothelium. Life Sci. 60, 325–334
13 Jantzen, F., Koneman, S., Wolff, B. et al. (2007) Isoprenoid
depletion by statins antagonizes cytokine-induced
down-regulation of endothelial nitric oxide expression
and increases NO synthase activity in human umbilical
vein endothelial cells. J. Physiol. Pharmacol. 58, 503–514
14 Gao, X., Belmadani, S., Picchi, A. et al. (2007) Tumor
necrosis factor-α induces endothelial dysfunction in
Leprdb mice. Circulation 115, 245–254
15 Picchi, A., Gao, X., Belmadani, S. et al. (2006) Tumor
necrosis factor-α induces endothelial dysfunction in the
prediabetic metabolic syndrome. Circ. Res. 99, 69–77
16 Aoki, N., Siegfried, M. and Lefer, A. M. (1989)
Anti-EDRF effect of tumor necrosis factor in isolated,
perfused cat carotid arteries. Am. J. Physiol. 256,
H1509–H1512
17 Ahmad, M., Zhang, Y., Papharalambus, C. and Alexander,
R. W. (2002) Role of isoprenylcysteine carboxyl
methyltransferase in tumor necrosis factor-α stimulation
of expression of vascular cell adhesion molecule-1 in
endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22,
759–764
18 Zhang, C., Xu, X., Potter, B. J. et al. (2006) TNF-α
contributes to endothelial dysfunction in
ischemia/reperfusion injury. Arterioscler. Thromb.
Vasc. Biol. 26, 475–480
19 Greenberg, S., Xie, J., Wang, Y. et al. (1993) Tumor
necrosis factor-α inhibits endothelium-dependent
relaxation. J. Appl. Physiol. 74, 2394–2403
20 Xie, L., Hattori, Y., Tume, N. and Gross, S. S. (2000)
The preferred source of arginine for high-output nitric
oxide synthesis in blood vessels. Semin. Perinatol. 24,
42–45
21 Goodwin, B. L., Solomonson, L. P. and Eichler, D. C.
(2004) Argininosuccinate synthase expression is
required to maintain nitric oxide production and cell
viability in aortic endothelial cells. J. Biol. Chem. 279,
18353–18360
22 Hattori, Y., Campbell, E. B. and Gross, S. S. (1994)
Argininosuccinate synthetase mRNA and activity are
induced by immunostimulants in vascular smooth muscle.
Role in the regeneration or arginine for nitric oxide
synthesis. J. Biol. Chem. 269, 9405–9408
23 Husson, A., Brasse-Lagnel, C., Fairand, A., Renouf, S.
and Lavoinne, A. (2003) Argininosuccinate synthetase
from the urea cycle to the citrulline-NO cycle.
Eur. J. Biochem. 270, 1887–1899
24 Oyadomari, S., Gotoh, T., Aoyagi, K., Araki, E.,
Shichiri, M. and Mori, M. (2001) Coinduction of
endothelial nitric oxide synthase and arginine recycling
enzymes in aorta of diabetic rats. Nitric Oxide 5, 252–260
25 Feletou, M. and Vanhoutte, P. M. (2006) Endothelial
dysfunction: a multifaceted disorder. Am. J. Physiol.
Heart Circ. Physiol. 291, H985–H1002
26 Fitzgerald, S. M., Kemp-Harper, B. K., Tare, M. and
Parkington, H. C. (2005) Role of endothelium-derived
hyperpolarizing factor in endothelial dysfunction during
diabetes. Clin. Exp. Pharmacol. Physiol. 32, 482–487
27 De Vriese, A. S., Verbeuren, T. J., Van de Voorde, J.,
Lameire, N. H. and Vanhoutte, P. M. (2000)
Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130,
963–974
28 Wimalasundera, R., Fexby, S., Regan, L., Thom, S. A. and
Hughes, A. D. (2003) Effect of tumour necrosis factor-α
and interleukin 1β on endothelium-dependent relaxation
in rat mesenteric resistance arteries in vitro.
Br. J. Pharmacol. 138, 1285–1294
29 Gillham, J. C., Myers, J. E., Baker, P. N. and Taggart, M. J.
(2008) TNF-α alters nitric oxide- and endothelium-
derived hyperpolarizing factor-mediated
vasodilatation in human omental arteries. Hypertens.
Pregnancy 27, 29–38
30 Kessler, P., Popp, R., Busse, R. and Schini-Kerth, V. B.
(1999) Proinﬂammatory mediators chronically
downregulate the formation of the endothelium-derived
hyperpolarizing factor in arteries via a nitric oxide/cyclic
GMP-dependent mechanism. Circulation 99,
1878–1884
30a Park, Y., Capobianco, S., Gao, X., Falck, J. R., Dellsperger,
K. C. and Zhang, C. (2008) Role of EDHF in Type 2
diabetes-induced endothelial dysfunction. Am. J. Physiol.
Heart Circ. Physiol., doi:10.1152/ajpheart.01261.2007
31 De Martin, R., Hoeth, M., Hofer-Warbinek, R. and
Schmid, J. A. (2000) The transcription factor NF-κBa n d
the regulation of vascular cell function.
Arterioscler. Thromb. Vasc. Biol. 20, E83–E88
32 Ye, J., Wang, L., Zhang, X., Tantishaiyakul, V. and
Rojanasakul, Y. (2003) Inhibition of TNF-α gene
expression and bioactivity by site-speciﬁc transcription
factor-binding oligonucleotides. Am. J. Physiol. Lung
Cell. Mol. Physiol. 284, L386–L394
33 Sorescu, D. and Griendling, K. K. (2002) Reactive oxygen
species, mitochondria, and NAD(P)H oxidases in the
development and progression of heart failure. Congest.
Heart Failure 8, 132–140
34 Downey, J. M., Omar, B., Ooiwa, H. and McCord, J.
(1991) Superoxide dismutase therapy for myocardial
ischemia. Free Radical Res. Commun. 12–13, 703–720
35 Pritchard, Jr, K. A., Groszek, L., Smalley, D. M. et al.
(1995) Native low-density lipoprotein increases
endothelial cell nitric oxide synthase generation of
superoxide anion. Circ. Res. 77, 510–518
36 Cai, H. and Harrison, D. G. (2000) Endothelial
dysfunction in cardiovascular diseases: the role of oxidant
stress. Circ. Res. 87, 840–844
37 Rajagopalan, S., Kurz, S., Munzel, T. et al. (1996)
Angiotensin II-mediated hypertension in the rat increases
vascular superoxide production via membrane
NADH/NADPH oxidase activation. Contribution to
alterations of vasomotor tone. J. Clin. Invest. 97,
1916–1923
38 Ushio-Fukai, M., Zafari, A. M., Fukui, T., Ishizaka, N.
and Griendling, K. K. (1996) p22phox is a critical
component of the superoxide-generating
NADH/NADPH oxidase system and regulates
angiotensin II-induced hypertrophy in vascular smooth
muscle cells. J. Biol. Chem. 271, 23317–23321
39 White, C. R., Darley-Usmar, V., Berrington, W. R. et al.
(1996) Circulating plasma xanthine oxidase contributes to
vascular dysfunction in hypercholesterolemic rabbits.
Proc. Natl. Acad. Sci. U.S.A. 93, 8745–8749
40 Vasquez-Vivar, J., Kalyanaraman, B., Martasek, P. et al.
(1998) Superoxide generation by endothelial nitric oxide
synthase: the inﬂuence of cofactors. Proc. Natl. Acad.
Sci. U.S.A. 95, 9220–9225
41 Warnholtz, A., Nickenig, G., Schulz, E. et al. (1999)
Increased NADH-oxidase-mediated superoxide
production in the early stages of atherosclerosis: evidence
for involvement of the renin-angiotensin system.
Circulation 99, 2027–2033
42 Azumi, H., Inoue, N., Takeshita, S. et al. (1999)
Expression of NADH/NADPH oxidase p22phox in
human coronary arteries. Circulation 100, 1494–1498
43 Guzik, T. J., West, N. E., Black, E. et al. (2000) Vascular
superoxide production by NAD(P)H oxidase: association
with endothelial dysfunction and clinical risk factors.
Circ. Res. 86, E85–E90
C   The Authors Journal compilation C   2009 Biochemical Society
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.228 H. Zhang and others
44 Griendling, K. K., Sorescu, D. and Ushio-Fukai, M.
(2000) NAD(P)H oxidase: role in cardiovascular biology
and disease. Circ. Res. 86, 494–501
45 Guzik, T. J., Mussa, S., Gastaldi, D. et al. (2002)
Mechanisms of increased vascular superoxide production
in human diabetes mellitus: role of NAD(P)H oxidase and
endothelial nitric oxide synthase. Circulation 105,
1656–1662
46 Feng, L., Matsumoto, C., Schwartz, A., Schmidt, A. M.,
Stern, D. M. and Pile-Spellman, J. (2005) Chronic vascular
inﬂammation in patients with type 2 diabetes: endothelial
biopsy and RT-PCR analysis. Diabetes Care 28,
379–384
47 Zou, W., Amcheslavsky, A., Takeshita, S., Drissi, H. and
Bar-Shavit, Z. (2005) TNF-α expression is
transcriptionally regulated by RANK ligand.
J. Cell. Physiol. 202, 371–378
48 Tanaka, N., Yonekura, H., Yamagishi, S., Fujimori, H.,
Yamamoto, Y. and Yamamoto, H. (2000) The receptor for
advanced glycation end products is induced by the
glycation products themselves and tumor necrosis
factor-α through nuclear factor-κB ,a n db y1 7 β-estradiol
through Sp-1 in human vascular endothelial cells.
J. Biol. Chem. 275, 25781–25790
4 9 Y a o ,J . ,M a c k m a n ,N . ,E d g i n g t o n ,T .S .a n dF a n ,S .T .
(1997) Lipopolysaccharide induction of the tumor
necrosis factor-α promoter in human monocytic cells.
Regulation by Egr-1, c-Jun, and NF-κB transcription
factors. J. Biol. Chem. 272, 17795–17801
50 Santee, S. M. and Owen-Schaub, L. B. (1996) Human
tumor necrosis factor receptor p75/80 (CD120b) gene
structure and promoter characterization. J. Biol. Chem.
271, 21151–21159
51 dela Paz, N. G., Simeonidis, S., Leo, C., Rose, D. W. and
Collins, T. (2007) Regulation of NF-κB-dependent gene
expression by the POU domain transcription factor
Oct-1. J. Biol. Chem. 282, 8424–8434
52 Rimbach, G., Valacchi, G., Canali, R. and Virgili, F. (2000)
Macrophages stimulated with IFN-γ activate NF-κBa n d
induce MCP-1 gene expression in primary human
endothelial cells. Mol. Cell. Biol. Res. Commun. 3,
238–242
53 Kumar, A., Takada, Y., Boriek, A. M. and Aggarwal, B. B.
(2004) Nuclear factor-κB: its role in health and disease.
J. Mol. Med. 82, 434–448
54 Bonizzi, G., Bebien, M., Otero, D. C. et al. (2004)
Activation of IKKα target genes depends on recognition
of speciﬁc κB binding sites by RelB:p52 dimers. EMBO J.
23, 4202–4210
55 Lawrence, T., Bebien, M., Liu, G. Y., Nizet, V. and
Karin, M. (2005) IKKα limits macrophage NF-κB
activation and contributes to the resolution of
inﬂammation. Nature 434, 1138–1143
56 Tran, K., Merika, M. and Thanos, D. (1997) Distinct
functional properties of IκBα and IκBβ. Mol. Cell. Biol.
17, 5386–5399
57 Lee, E. G., Boone, D. L., Chai, S. et al. (2000) Failure to
regulate TNF-induced NF-κB and cell death responses in
A20-deﬁcient mice. Science 289, 2350–2354
58 Russo, G., Leopold, J. A. and Loscalzo, J. (2002)
Vasoactive substances: nitric oxide and endothelial
dysfunction in atherosclerosis. Vasc. Pharmacol. 38,
259–269
59 Shoelson, S. E., Herrero, L. and Naaz, A. (2007) Obesity,
inﬂammation, and insulin resistance. Gastroenterology
132, 2169–2180
60 Steinberg, H. O., Chaker, H., Leaming, R., Johnson, A.,
Brechtel, G. and Baron, A. D. (1996) Obesity/insulin
resistance is associated with endothelial dysfunction.
Implications for the syndrome of insulin resistance.
J. Clin. Invest. 97, 2601–2610
61 Cleland, S. J., Petrie, J. R., Ueda, S., Elliott, H. L. and
Connell, J. M. (1999) Insulin-mediated vasodilation
and glucose uptake are functionally linked in humans.
Hypertension 33, 554–558
62 Jovinge, S., Hamsten, A., Tornvall, P. et al. (1998) Evidence
for a role of tumor necrosis factor α in disturbances of
triglyceride and glucose metabolism predisposing to
coronary heart disease. Metab. Clin. Exp. 47, 113–118
63 Zubelewicz-Szkodzinska, B., Szkodzinski, J.,
Romanowski, W. et al. (2004) Simvastatin decreases
concentration of interleukin-2 in hypercholesterolemic
patients after treatment for 12 weeks. J. Biol. Regul.
Homeost. Agents 18, 295–301
64 Ascer, E., Bertolami, M. C., Venturinelli, M. L. et al.
(2004) Atorvastatin reduces proinﬂammatory markers in
hypercholesterolemic patients. Atherosclerosis 177,
161–166
65 Marketou, M. E., Zacharis, E. A., Nikitovic, D. et al.
(2006) Early effects of simvastatin versus atorvastatin on
oxidative stress and proinﬂammatory cytokines in
hyperlipidemic subjects. Angiology 57, 211–218
66 Okopien, B., Krysiak, R., Kowalski, J. et al. (2005)
Monocyte release of tumor necrosis factor-α and
interleukin-1β in primary type IIa and IIb dyslipidemic
patients treated with statins or ﬁbrates.
J. Cardiovasc. Pharmacol. 46, 377–386
6 7 Z h a o ,S .P . ,W u ,Z .H . ,W u ,J . ,H o n g ,S .C .a n dD e n g ,P .
(2005) Effect of atorvastatin on tumor necrosis factor α
serum concentration and mRNA expression of adipose in
hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol.
46, 185–189
68 Popa, C., Netea, M. G., Radstake, T. et al. (2005)
Inﬂuence of anti-tumour necrosis factor therapy on
cardiovascular risk factors in patients with active
rheumatoid arthritis. Ann. Rheum. Dis. 64, 303–305
69 Cauza, E., Cauza, K., Hanusch-Enserer, U., Etemad, M.,
Dunky, A. and Kostner, K. (2002) Intravenous anti
TNF-α antibody therapy leads to elevated triglyceride
and reduced HDL-cholesterol levels in patients with
rheumatoid and psoriatic arthritis.
Wien. Klin. Wochenschr. 114, 1004–1007
70 Spanakis, E., Sidiropoulos, P., Papadakis, J. et al. (2006)
Modest but sustained increase of serum high density
lipoprotein cholesterol levels in patients with
inﬂammatory arthritides treated with inﬂiximab.
J. Rheumatol. 33, 2440–2446
71 Vis, M., Nurmohamed, M. T., Wolbink, G. et al. (2005)
Short term effects of inﬂiximab on the lipid proﬁle in
patients with rheumatoid arthritis. J. Rheumatol. 32,
252–255
72 Memon, R. A., Grunfeld, C., Moser, A. H. and Feingold,
K. R. (1993) Tumor necrosis factor mediates the effects of
endotoxin on cholesterol and triglyceride metabolism in
mice. Endocrinology 132, 2246–2253
73 Feingold, K. R., Marshall, M., Gulli, R., Moser, A. H. and
Grunfeld, C. (1994) Effect of endotoxin and cytokines on
lipoprotein lipase activity in mice. Arterioscler. Thromb.
14, 1866–1872
74 Csiszar, A., Labinskyy, N., Smith, K., Rivera, A.,
Orosz, Z. and Ungvari, Z. (2007) Vasculoprotective
effects of anti-tumor necrosis factor-α treatment in aging.
Am. J. Pathol. 170, 388–398
75 Bruunsgaard, H., Skinhoj, P., Pedersen, A. N., Schroll, M.
and Pedersen, B. K. (2000) Ageing, tumour necrosis
factor-α (TNF-α) and atherosclerosis.
Clin. Exp. Immunol. 121, 255–260
76 Belmin, J., Bernard, C., Corman, B., Merval, R.,
Esposito, B. and Tedgui, A. (1995) Increased production
of tumor necrosis factor and interleukin-6 by arterial wall
of aged rats. Am. J. Physiol. 268, H2288–H2293
77 Csiszar, A., Ungvari, Z., Koller, A., Edwards, J. G. and
Kaley, G. (2004) Proinﬂammatory phenotype of coronary
arteries promotes endothelial apoptosis in aging.
Physiol. Genomics 17, 21–30
78 Shimada, Y., Ito, H., Kaji, K. and Fukuda, M. (1990)
Tumor necrosis factor reduces lifespan of human
endothelial cells in vitro. Mech. Ageing Dev. 55, 245–254
79 Arenas, I. A., Xu, Y. and Davidge, S. T. (2006)
Age-associated impairment in vasorelaxation to ﬂuid
shear stress in the female vasculature is improved by
TNF-α antagonism. Am. J. Physiol. Heart Circ. Physiol.
290, H1259–H1263
80 Giannattasio, C., Zoppo, A., Gentile, G. et al. (2005)
Acute effect of high-fat meal on endothelial function in
moderately dyslipidemic subjects. Arterioscler. Thromb.
Vasc. Biol. 25, 406–410
C   The Authors Journal compilation C   2009 Biochemical Society
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.Role of TNF-α in vascular dysfunction 229
81 Esposito, K., Ciotola, M., Sasso, F. C. et al. (2007) Effect of
a single high-fat meal on endothelial function in patients
with the metabolic syndrome: role of tumor necrosis
factor-α. Nutr. Metab. Cardiovasc. Dis. 17, 274–279
82 Nappo, F., Esposito, K., Ciofﬁ, M. et al. (2002)
Postprandial endothelial activation in healthy subjects and
in type 2 diabetic patients: role of fat and carbohydrate
meals. J. Am. Coll. Cardiol. 39, 1145–1150
83 Fujiyama, Y., Hokari, R., Miura, S. et al. (2007) Butter
feeding enhances TNF-α production from macrophages
and lymphocyte adherence in murine small intestinal
microvessels. J. Gastroenterol. Hepatol. 22, 1838–1845
84 Hennig, B., Toborek, M. and McClain, C. J. (2001)
High-energy diets, fatty acids and endothelial cell
function: implications for atherosclerosis. J. Am.
Coll. Nutr. 20, 97–105
85 Willerson, J. T. and Ridker, P. M. (2004) Inﬂammation as a
cardiovascular risk factor. Circulation 109, II2–II10
86 Bruunsgaard, H. (2005) Physical activity and modulation
of systemic low-level inﬂammation. J. Leukocyte Biol. 78,
819–835
87 Keller, C., Keller, P., Giralt, M., Hidalgo, J. and Pedersen,
B. K. (2004) Exercise normalises overexpression of
TNF-α in knockout mice. Biochem. Biophys.
Res. Commun. 321, 179–182
88 Flynn, M., McFarlin, B. K. and Markofski, M. A. (2007)
The anti-inﬂammatory actions of exercise training. Am. J.
Lifestyle Med. 1, 220–235
89 de Lemos, E. T., Reis, F., Baptista, S. et al. (2007) Exercise
training is associated with improved levels of C-reactive
protein and adiponectin in ZDF (type 2) diabetic rats.
Med. Sci. Monit. 13, BR168–BR174
90 Das, U. N. (2004) Anti-inﬂammatory nature of exercise.
Nutrition 20, 323–326
91 Valgimigli, M., Rigolin, G. M., Fucili, A. et al. (2004)
CD34+ and endothelial progenitor cells in patients with
various degrees of congestive heart failure. Circulation
110, 1209–1212
92 Iversen, P. O., Woldbaek, P. R., Tonnessen, T. and
Christensen, G. (2002) Decreased hematopoiesis in bone
marrow of mice with congestive heart failure. Am. J.
Physiol. Regul. Integr. Comp. Physiol. 282, R166–R172
93 Rusten, L. S., Smeland, E. B., Jacobsen, F. W. et al. (1994)
Tumor necrosis factor-α inhibits stem cell factor-induced
proliferation of human bone marrow progenitor cells
in vitro. Role of p55 and p75 tumor necrosis factor
receptors. J. Clin. Invest. 94, 165–172
94 Hu, X., Tang, M., Fisher, A. B., Olashaw, N. and
Zuckerman, K. S. (1999) TNF-α-induced growth
suppression of CD34+ myeloid leukemic cell lines signals
through TNF receptor type I and is associated with
NF-κB activation. J. Immunol. 163, 3106–3115
95 Ramsfjell, V., Borge, O. J., Cui, L. and Jacobsen, S. E.
(1997) Thrombopoietin directly and potently stimulates
multilineage growth and progenitor cell expansion from
primitive (CD34+ CD38−) human bone marrow
progenitor cells: distinct and key interactions with the
ligands for c-kit and ﬂt3, and inhibitory effects of TGF-β
and TNF-α. J. Immunol. 158, 5169–5177
96 Chen, Y., Ke, Q., Yang, Y. et al. (2003) Cardiomyocytes
overexpressing TNF-α attract migration of embryonic
stem cells via activation of p38 and c-Jun amino-terminal
kinase. FASEB J. 17, 2231–2239
97 Bao, C., Guo, J., Lin, G., Hu, M. and Hu, Z. (2007)
TNFR gene-modiﬁed mesenchymal stem cells attenuate
inﬂammation and cardiac dysfunction following MI.
Scand. Cardiovasc. J. 42, 56–62
98 Goukassian, D. A., Qin, G., Dolan, C. et al. (2007) Tumor
necrosis factor-α receptor p75 is required in
ischemia-induced neovascularization. Circulation 115,
752–762
99 Munker, R., Gasson, J., Ogawa, M. and Koefﬂer, H. P.
(1986) Recombinant human TNF induces production of
granulocyte-monocyte colony-stimulating factor. Nature
323, 79–82
100 Nishiwaki, Y., Yoshida, M., Iwaguro, H. et al. (2007)
Endothelial E-selectin potentiates neovascularization via
endothelial progenitor cell-dependent and -independent
mechanisms. Arterioscler. Thromb. Vasc. Biol. 27,
512–518
101 Fahlman, C., Jacobsen, F. W., Veiby, O. P., McNiece, I. K.,
Blomhoff, H. K. and Jacobsen, S. E. (1994) Tumor
necrosis factor-α (TNF-α) potently enhances in vitro
macrophage production from primitive murine
hematopoietic progenitor cells in combination with stem
cell factor and interleukin-7: novel stimulatory role of p55
TNF receptors. Blood 84, 1528–1533
102 Chia, S., Qadan, M., Newton, R., Ludlam, C. A., Fox,
K. A. and Newby, D. E. (2003) Intra-arterial tumor
necrosis factor-α impairs endothelium-dependent
vasodilatation and stimulates local tissue plasminogen
activator release in humans. Arterioscler. Thromb.
Vasc. Biol. 23, 695–701
103 Nakamura, M., Yoshida, H., Arakawa, N., Saitoh, S.,
Satoh, M. and Hiramori, K. (2000) Effects of tumor
necrosis factor-α on basal and stimulated
endothelium-dependent vasomotion in human resistance
vessel. J. Cardiovasc. Pharmacol. 36, 487–492
104 Robinson, S. D., Dawson, P., Ludlam, C. A., Boon, N. A.
and Newby, D. E. (2006) Vascular and ﬁbrinolytic effects
of intra-arterial tumour necrosis factor-α in patients with
coronary heart disease. Clin. Sci. 110, 353–360
105 Martens, F. M., Rabelink, T. J., op ‘t Roodt, J., de Koning,
E. J. and Visseren, F. L. (2006) TNF-α induces endothelial
dysfunction in diabetic adults, an effect reversible by the
PPAR-γ agonist pioglitazone. Eur. Heart J. 27,
1605–1609
106 Hurlimann, D., Forster, A., Noll, G. et al. (2002)
Anti-tumor necrosis factor-α treatment improves
endothelial function in patients with rheumatoid arthritis.
Circulation 106, 2184–2187
107 Cardillo, C., Schinzari, F., Mores, N. et al. (2006)
Intravascular tumor necrosis factor α blockade reverses
endothelial dysfunction in rheumatoid arthritis.
Clin. Pharmacol. Ther. 80, 275–281
108 Booth, A. D., Jayne, D. R., Kharbanda, R. K. et al. (2004)
Inﬂiximab improves endothelial dysfunction in systemic
vasculitis: a model of vascular inﬂammation. Circulation
109, 1718–1723
109 Schinzari, F., Armuzzi, A., De Pascalis, B. et al. (2008)
Tumor necrosis factor-α antagonism improves endothelial
dysfunction in patients with Crohn’s disease.
Clin. Pharmacol. Ther. 83, 70–76
110 Bilsborough, W., Keen, H., Taylor, A., O’Driscoll, G. J.,
Arnolda, L. and Green, D. J. (2006) Anti-tumour necrosis
factor-α therapy over conventional therapy improves
endothelial function in adults with rheumatoid arthritis.
Rheumatol. Int. 26, 1125–1131
111 Gonzalez-Juanatey, C., Llorca, J., Sanchez-Andrade, A.,
Garcia-Porrua, C., Martin, J. and Gonzalez-Gay, M. A.
(2006) Short-term adalimumab therapy improves
endothelial function in patients with rheumatoid arthritis
refractory to inﬂiximab. Clin. Exp. Rheumatol. 24,
309–312
112 Fichtlscherer, S., Rossig, L., Breuer, S., Vasa, M.,
Dimmeler, S. and Zeiher, A. M. (2001) Tumor necrosis
factor antagonism with etanercept improves systemic
endothelial vasoreactivity in patients with advanced heart
failure. Circulation 104, 3023–3025
113 Mann, D. L., McMurray, J. J., Packer, M. et al. (2004)
Targeted anticytokine therapy in patients with chronic
heart failure: results of the Randomized Etanercept
Worldwide Evaluation (RENEWAL). Circulation 109,
1594–1602
C   The Authors Journal compilation C   2009 Biochemical Society
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.230 H. Zhang and others
114 Dominguez, H., Storgaard, H., Rask-Madsen, C. et al.
(2005) Metabolic and vascular effects of tumor necrosis
factor-α blockade with etanercept in obese patients with
type 2 diabetes. J. Vasc. Res. 42, 517–525
115 Radaelli, A., Loardi, C., Cazzaniga, M. et al. (2007)
Inﬂammatory activation during coronary artery surgery
and its dose-dependent modulation by
statin/ACE-inhibitor combination. Arterioscler. Thromb.
Vasc. Biol. 27, 2750–2755
116 Sola, S., Mir, M. Q., Lerakis, S., Tandon, N. and Khan,
B. V. (2006) Atorvastatin improves left ventricular systolic
function and serum markers of inﬂammation in
nonischemicheartfailure. J.Am.Coll.Cardiol. 47, 332–337
117 Kovacs, I., Toth, J., Tarjan, J. and Koller, A. (2006)
Correlation of ﬂow mediated dilation with inﬂammatory
markers in patients with impaired cardiac function.
Beneﬁcial effects of inhibition of ACE. Eur. J.
Heart Failure 8, 451–459
118 Tikiz, C., Utuk, O., Pirildar, T. et al. (2005) Effects of
angiotensin-converting enzyme inhibition and statin
treatment on inﬂammatory markers and endothelial
functions in patients with longterm rheumatoid arthritis.
J. Rheumatol. 32, 2095–2101
119 Tousoulis, D., Antoniades, C., Vassiliadou, C. et al. (2005)
Effects of combined administration of low dose
atorvastatin and vitamin E on inﬂammatory markers and
endothelial function in patients with heart failure. Eur. J
Heart Failure 7, 1126–1132
120 Koh, K. K., Son, J. W., Ahn, J. Y. et al. (2004) Vascular
effects of diet and statin in hypercholesterolemic patients.
Int. J. Cardiol. 95, 185–191
121 Economides, P. A., Caselli, A., Tiani, E., Khaodhiar, L.,
Horton, E. S. and Veves, A. (2004) The effects of
atorvastatin on endothelial function in diabetic patients
and subjects at risk for type 2 diabetes. J. Clin.
Endocrinol. Metab. 89, 740–747
Received 3 June 2008/22 July 2008; accepted 12 August 2008
Published on the Internet 8 January 2009, doi:10.1042/CS20080196
C   The Authors Journal compilation C   2009 Biochemical Society
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.